Cytiva Sera-Xtracta Virus/Pathogen Kit

Description

• Sera-Xtracta Virus/Pathogen Kit for high-throughput total nucleic acid (DNA/RNA) isolation from bacteria and viruses including Adenovirus (Type 14), Influenza A (H3N2) and COVID-19.
• Offers the advantages of solid phase extraction (using magnetic beads) and reproducible yields.
• Simplified protocol can be adapted for both manual and automated high-throughput processing.
• Scalable up to 400 μL of sample.
• Rapid extraction procedure can be completed in less than 30 minutes.
• For use with respiratory biological matrices, blood and universal transport media to support the sensitive downstream detection of viruses and other pathogens found in low concentrations.
• Compatible with molecular biology techniques, including quantitative polymerase chain reaction (qPCR, RT-qPCR), droplet digital PCR (ddPCR), and next-generation sequencing (NGS).
• Sera-Xtracta Virus/Pathogen Kit provides a simple and rapid method to optimize the workflow for sensitive detection system for viruses and other pathogens found in low concentrations.
• Optimize isolation workflows to reduce bottlenecks
• To address this bottleneck, our robust extraction chemistry ensures that the total nucleic acid is selectively bound to the superparamagnetic beads, while impurities are efficiently removed during the quick wash steps.
• The resulting high quality total nucleic acid is then eluted from the bead using a suitable elution buffer of choice.
• The rapid Sera-Xtracta workflow gives pure, high-quality nucleic acid suitable for sensitive molecular testing.

Infectious diseases affect millions of people every year. Particularly virulent and multi-drug resistant agents are increasingly responsible for infections with ever-expanding complexities. The design, manufacture and validation of assays for these pathogenic agents requires the successful purification of high-quality nucleic acid. This is essential to any molecular research and testing workflow. The nucleic acid purification process can be a bottleneck because sufficient nucleic acid from biological samples is required to meet a sensitivity threshold for assays which are designed to help identify, map or make informed decisions on latent and active infections.